Cooperative Agreement 2404500

This Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $999,545 to Senoguard Inc., a woman-owned small business, to develop and validate a novel minimally invasive cryoablation probe system for post-lumpectomy adjunct therapy. The project aims to complete engineering, materials selection, and testing activities for the cryogenic probe and external controller, with the goal of creating a treatment paradigm to reduce side effects and follow-up visits for breast cancer patients undergoing lumpectomy. The initiative intends to advance this cryoablation technology through ex vivo tissue experiments and in vivo ovine studies to demonstrate system efficacy and safety prior to human use. The project has been deemed worthy of support by the NSF based on its potential for technological innovation and broader societal and economic impacts in the $7.5B annual breast cancer treatment market.